Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > And That's Not All

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Mar 04, 2023 3:51pm

150 Views

Post# 35319444

RE:And That's Not All

Cohort 1 of GOBLET was for first-line metastatic PDAC patients.

On December 1, 2022 we are advised that ONC/ONCY has received FDA Fast Track Designation for Advanced/Metastatic PDAC. Can one assume that Advanced and Metastatic are the same thing. I do not think the term Advanced was used in the beginning.

I guess I am asking if the Fast Track designation applies to a broader group than Cohort 1.

TIA

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec